A Phase 3 interventional study of one dose test vaccine and one dose commercially available trivalent influenza vaccine in Quadrivalent Influenza Virus Vaccine, sponsored by Beijing Chaoyang District Centre for Disease Control and Prevention. Status unknown. Open to participants aged 3 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-21.
Sponsored by Beijing Chaoyang District Centre for Disease Control and Prevention · Phase 3, Interventional, and Prevention
This study evaluates the safety and immunogenicity of the quadrivalent influenza virus vaccine in healthy people aged years 3-60.Subjects will be randomly divided into 3 groups,receiving the test vaccine, commercially available trivalent influenza vaccine and trivalent influenza vaccine containing new influenza B component respectively. Each group has 800 subjects,2400 in total.
2,214 studies on the registry are indexed under Influenza, Human; 163 are open to participants now.
This study's planned enrollment of 2,400 is above the median of 238 across 1,853 interventional studies indexed under Influenza, Human.
Browse Influenza, Human studies →Beijing Chaoyang District Centre for Disease Control and Prevention is the lead sponsor of 11 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
One dose of quadrivalent influenza virus vaccine will be randomly given in aged 3-60 years old.
Biological: one dose test vaccine
One dose of trivalent influenza virus vaccine will be randomly given in aged 3-60 years old.
Biological: one dose commercially available trivalent influenza vaccine
One dose of quadrivalent influenza virus vaccine (trivalent influenza virus vaccine added to a new influenza B component) will be randomly given in aged 3-60 years old.
Biological: One dose of Quadrivalent Influenza Virus Vaccine
Evaluate serum antibody titers of quadrivalent influenza Vaccine in healthy people.
The serum antibody titers will be evaluated at 28 days after vaccination.
Time frame: 28 days
Evaluate the Rate of Adverse reactions of quadrivalent influenza Vaccine in healthy people.
Adverse reactions associated with vaccine will be observed in subjects after vaccination. Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy.
Time frame: 28 days
No study locations are listed for this record.
This study is status unknown, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Chaoyang District Centre for Disease Control and Prevention